Twist Bioscience (NASDAQ:TWST) Stock Price Expected to Rise, Scotiabank Analyst Says

Twist Bioscience (NASDAQ:TWST) had its price target lifted by Scotiabank from $50.00 to $54.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm presently has a “sector outperform” rating on the stock. Scotiabank’s price objective points to a potential upside of 31.35% from the stock’s current price.

A number of other research firms also recently issued reports on TWST. Evercore ISI upped their price target on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Barclays decreased their price objective on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a research report on Monday, August 5th. Robert W. Baird raised their target price on shares of Twist Bioscience from $46.00 to $48.00 and gave the stock an “outperform” rating in a report on Tuesday. Leerink Partners upped their price target on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a report on Thursday, October 17th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research note on Monday, August 5th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $51.78.

Twist Bioscience Stock Performance

TWST opened at $41.11 on Tuesday. Twist Bioscience has a fifty-two week low of $23.07 and a fifty-two week high of $60.90. The stock has a market cap of $2.41 billion, a price-to-earnings ratio of -10.76 and a beta of 1.78. The firm’s fifty day moving average is $43.93 and its 200 day moving average is $46.15.

Insider Buying and Selling

In other news, CFO Adam Laponis sold 856 shares of Twist Bioscience stock in a transaction on Wednesday, October 9th. The stock was sold at an average price of $41.81, for a total transaction of $35,789.36. Following the transaction, the chief financial officer now owns 73,397 shares in the company, valued at $3,068,728.57. The trade was a 1.15 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Dennis Cho sold 1,507 shares of the business’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $48.00, for a total transaction of $72,336.00. Following the completion of the transaction, the insider now owns 91,163 shares in the company, valued at $4,375,824. The trade was a 1.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 98,118 shares of company stock worth $4,391,151 in the last 90 days. Insiders own 3.92% of the company’s stock.

Institutional Investors Weigh In On Twist Bioscience

A number of institutional investors have recently made changes to their positions in TWST. American International Group Inc. lifted its holdings in Twist Bioscience by 0.8% during the 1st quarter. American International Group Inc. now owns 28,506 shares of the company’s stock worth $978,000 after buying an additional 213 shares in the last quarter. Caprock Group LLC raised its stake in Twist Bioscience by 2.9% in the second quarter. Caprock Group LLC now owns 7,851 shares of the company’s stock valued at $387,000 after buying an additional 220 shares in the last quarter. Signaturefd LLC increased its holdings in shares of Twist Bioscience by 63.0% in the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after acquiring an additional 306 shares during the last quarter. Arizona State Retirement System increased its stake in Twist Bioscience by 1.9% in the second quarter. Arizona State Retirement System now owns 16,187 shares of the company’s stock valued at $798,000 after purchasing an additional 308 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA grew its position in shares of Twist Bioscience by 3.5% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 9,279 shares of the company’s stock valued at $457,000 after buying an additional 312 shares during the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.